210 related articles for article (PubMed ID: 14680807)
1. Cloning and expression analysis of a Parkinson's disease gene, uch-L1, and its promoter in zebrafish.
Son OL; Kim HT; Ji MH; Yoo KW; Rhee M; Kim CH
Biochem Biophys Res Commun; 2003 Dec; 312(3):601-7. PubMed ID: 14680807
[TBL] [Abstract][Full Text] [Related]
2. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
[TBL] [Abstract][Full Text] [Related]
3. Aberrant molecular properties shared by familial Parkinson's disease-associated mutant UCH-L1 and carbonyl-modified UCH-L1.
Kabuta T; Setsuie R; Mitsui T; Kinugawa A; Sakurai M; Aoki S; Uchida K; Wada K
Hum Mol Genet; 2008 May; 17(10):1482-96. PubMed ID: 18250096
[TBL] [Abstract][Full Text] [Related]
4. Microarray expression analysis of gad mice implicates involvement of Parkinson's disease associated UCH-L1 in multiple metabolic pathways.
Bonin M; Poths S; Osaka H; Wang YL; Wada K; Riess O
Brain Res Mol Brain Res; 2004 Jul; 126(1):88-97. PubMed ID: 15207921
[TBL] [Abstract][Full Text] [Related]
5. NF-κB signaling inhibits ubiquitin carboxyl-terminal hydrolase L1 gene expression.
Wang R; Zhang M; Zhou W; Ly PT; Cai F; Song W
J Neurochem; 2011 Mar; 116(6):1160-70. PubMed ID: 21210816
[TBL] [Abstract][Full Text] [Related]
6. Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function.
Contu VR; Kotake Y; Toyama T; Okuda K; Miyara M; Sakamoto S; Samizo S; Sanoh S; Kumagai Y; Ohta S
J Neurochem; 2014 Sep; 130(6):826-38. PubMed ID: 24832624
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease-associated mutations in α-synuclein and UCH-L1 inhibit the unconventional secretion of UCH-L1.
Konya C; Hatanaka Y; Fujiwara Y; Uchida K; Nagai Y; Wada K; Kabuta T
Neurochem Int; 2011 Aug; 59(2):251-8. PubMed ID: 21693148
[TBL] [Abstract][Full Text] [Related]
8. N-terminal truncated UCH-L1 prevents Parkinson's disease associated damage.
Kim HJ; Kim HJ; Jeong JE; Baek JY; Jeong J; Kim S; Kim YM; Kim Y; Nam JH; Huh SH; Seo J; Jin BK; Lee KJ
PLoS One; 2014; 9(6):e99654. PubMed ID: 24959670
[TBL] [Abstract][Full Text] [Related]
9. DJ-1 and UCH-L1 gene activity patterns in the brains of controls, Parkinson and schizophrenia patients and in rodents.
Galter D; Westerlund M; Belin AC; Olson L
Physiol Behav; 2007 Sep; 92(1-2):46-53. PubMed ID: 17599367
[TBL] [Abstract][Full Text] [Related]
10. Familial Mutations and Post-translational Modifications of UCH-L1 in Parkinson's Disease and Neurodegenerative Disorders.
Lee YC; Hsu SD
Curr Protein Pept Sci; 2017; 18(7):733-745. PubMed ID: 26899237
[TBL] [Abstract][Full Text] [Related]
11. Insights into links between familial and sporadic Parkinson's disease: physical relationship between UCH-L1 variants and chaperone-mediated autophagy.
Kabuta T; Wada K
Autophagy; 2008 Aug; 4(6):827-9. PubMed ID: 18635949
[TBL] [Abstract][Full Text] [Related]
12. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
13. Backbone and side-chain 1H, 15N and 13C resonance assignments of S18Y mutant of ubiquitin carboxy-terminal hydrolase L1.
Tse HS; Hu HY; Sze KH
Biomol NMR Assign; 2011 Oct; 5(2):165-8. PubMed ID: 21298373
[TBL] [Abstract][Full Text] [Related]
14. Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system.
Xilouri M; Kyratzi E; Pitychoutis PM; Papadopoulou-Daifoti Z; Perier C; Vila M; Maniati M; Ulusoy A; Kirik D; Park DS; Wada K; Stefanis L
Hum Mol Genet; 2012 Feb; 21(4):874-89. PubMed ID: 22076440
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of UCHL1 modulation on alpha-synuclein in PD-like models of alpha-synucleinopathy.
Cartier AE; Ubhi K; Spencer B; Vazquez-Roque RA; Kosberg KA; Fourgeaud L; Kanayson P; Patrick C; Rockenstein E; Patrick GN; Masliah E
PLoS One; 2012; 7(4):e34713. PubMed ID: 22514658
[TBL] [Abstract][Full Text] [Related]
16. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease.
Solano SM; Miller DW; Augood SJ; Young AB; Penney JB
Ann Neurol; 2000 Feb; 47(2):201-10. PubMed ID: 10665491
[TBL] [Abstract][Full Text] [Related]
17. The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells.
Kyratzi E; Pavlaki M; Stefanis L
Hum Mol Genet; 2008 Jul; 17(14):2160-71. PubMed ID: 18411255
[TBL] [Abstract][Full Text] [Related]
18. The functions of UCH-L1 and its relation to neurodegenerative diseases.
Setsuie R; Wada K
Neurochem Int; 2007; 51(2-4):105-11. PubMed ID: 17586089
[TBL] [Abstract][Full Text] [Related]
19. Parkin-mediated K63-polyubiquitination targets ubiquitin C-terminal hydrolase L1 for degradation by the autophagy-lysosome system.
McKeon JE; Sha D; Li L; Chin LS
Cell Mol Life Sci; 2015 May; 72(9):1811-24. PubMed ID: 25403879
[TBL] [Abstract][Full Text] [Related]
20. Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy.
Kabuta T; Furuta A; Aoki S; Furuta K; Wada K
J Biol Chem; 2008 Aug; 283(35):23731-8. PubMed ID: 18550537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
